Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

ImmuCell Corporation

Healthcare US ICCC

9.7USD
0.09(0.94%)

Last update at 2026-06-08T20:00:00Z

Day Range

9.619.99
LowHigh

52 Week Range

4.346.05
LowHigh

Fundamentals

  • Previous Close 9.61
  • Market Cap34.29M
  • Volume20807
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-2.50408M
  • Revenue TTM17.47M
  • Revenue Per Share TTM2.25
  • Gross Profit TTM 7648.78M
  • Diluted EPS TTM-0.49

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -2.48600M -0.06900M -1.03200M -1.26800M -1.86000M
Minority interest - - - - -
Net income -2.49400M -0.07800M -1.02200M -1.29600M -2.32200M
Selling general administrative 2.26M 1.73M 1.72M 1.69M 1.74M
Selling and marketing expenses 5.45M 4.23M 3.89M 4.01M 3.82M
Gross profit 7.65M 8.66M 6.86M 6.74M 5.19M
Reconciled depreciation 2.49M 2.46M 2.35M 2.27M 1.52M
Ebit -4.78658M -2.20414M -3.72728M -3.22142M -4.36771M
Ebitda -2.29900M 0.26M -1.38000M -0.95400M -2.84700M
Depreciation and amortization 2.49M 2.46M 2.35M 2.27M 1.52M
Non operating income net other - - 0.35M -0.31350M -0.41348M
Operating income -2.29900M -2.20414M -1.38000M -0.95400M -1.44700M
Other operating expenses 20.87M 18.99M 16.72M 14.68M 13.13M
Interest expense 0.34M 0.31M 0.41M 0.43M 0.43M
Tax provision 0.00800M 0.00900M -0.01000M 0.03M 0.46M
Interest income 0.15M 0.02M 0.03M 0.12M 0.01M
Net interest income -0.19544M -0.29555M -0.38525M -0.31350M -0.41348M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.00800M 0.00900M -0.01000M 0.03M 0.46M
Total revenue 18.57M 19.24M 15.34M 13.72M 10.99M
Total operating expenses 9.95M 8.40M 8.24M 7.69M 7.34M
Cost of revenue 10.92M 10.59M 8.48M 6.98M 5.79M
Total other income expense net -0.18700M 2.14M 0.35M -0.31400M 0.29M
Discontinued operations - - - - -
Net income from continuing ops -2.49400M -0.07800M -1.02200M -1.29559M -2.32167M
Net income applicable to common shares -2493.80500M -0.07800M -1.02200M -1.29559M -2.32167M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 43.81M 44.86M 44.47M 40.35M 38.69M
Intangible assets 0.04M 0.06M 0.08M 0.10M 0.11M
Earning assets - - - - -
Other current assets 0.45M 0.41M 0.27M 0.25M 0.22M
Total liab 18.82M 14.48M 11.89M 12.08M 9.70M
Total stockholder equity 24.99M 30.38M 32.58M 28.27M 28.99M
Deferred long term liab - - - - 0.06M
Other current liab 1.23M 1.21M 0.87M 0.75M 0.65M
Common stock 0.78M 0.78M 0.78M 0.73M 0.73M
Capital stock - 0.78M 0.78M 0.73M 0.73M
Retained earnings -12.00710M -6.23250M -3.73869M -3.66040M -2.63829M
Other liab - - - - -
Good will 0.10M 0.10M 0.10M 0.10M 0.10M
Other assets 0.00000M 0.00035M 0.00031M 0.00041M 0.00016M
Cash 0.98M 5.79M 10.19M 7.95M 8.77M
Cash and equivalents - - - - -
Total current liabilities 4.20M 3.07M 2.53M 2.21M 2.50M
Current deferred revenue 0.00305M - - - -
Net debt 15.71M 6.69M 0.09M 2.79M -0.35253M
Short term debt 2.07M 1.07M 0.92M 0.86M 1.27M
Short long term debt - 1.04M 0.81M 0.76M 1.27M
Short long term debt total 16.69M 12.48M 10.27M 10.73M 8.42M
Other stockholder equity 36.22M 35.83M 35.53M 31.20M 30.94M
Property plant equipment - 30636.40M 28.00M 27.98M 25.27M
Total current assets 11.47M 13.99M 16.26M 12.16M 13.19M
Long term investments - - - - -
Net tangible assets - 30227.18M 32.29M 27.82M 28.78M
Short term investments - - -0.00047M 1.00M 2.48M
Net receivables 2.23M 1.80M 2.72M 1.86M 1.68M
Long term debt - 9.19M 8.33M 8.74M 7.15M
Inventory 7.81M 6.04M 3.09M 2.09M 2.52M
Accounts payable 0.89M 0.79M 0.75M 0.60M 0.57M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00000M - - - -0.04390M
Additional paid in capital - - - - -
Common stock total equity - - - 0.73M 0.73M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -3.66040M -2.63829M
Treasury stock - - - -0.17539M -0.18834M
Accumulated amortization - - - - -
Non currrent assets other 0.06M 0.08M 0.03M 0.03M 0.03M
Deferred long term asset charges - - - - -
Non current assets total 32.34M 30.87M 28.20M 28.19M 25.50M
Capital lease obligations - 2.25M 1.14M 1.24M -
Long term debt total - - - 8.74M 7.15M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -3.96427M -1.59736M -2.56994M -2.00300M 0.25M
Change to liabilities 341.61M 0.25M 0.30M -0.08871M 0.06M
Total cashflows from investing activities -3964.27400M -1.59736M -2.56994M -3.40336M -1.79397M
Net borrowings 1102.88M -0.36827M 1.96M -1.36135M 0.79M
Total cash from financing activities 1.11M 3.88M 1.91M 6.94M 0.89M
Change to operating activities -161.37100M 0.03M -0.03373M -0.11543M 0.12M
Net income -2.49381M -0.07829M -1.02212M -1.29559M -2.32167M
Change in cash -4.39391M 3.24M 0.66M 3.77M -1.27776M
Begin period cash flow 10.19M 6.95M 6.29M 2.52M 3.80M
End period cash flow 5.79M 10.19M 6.95M 6.29M 2.52M
Total cash from operating activities -1.54387M 0.95M 1.32M 0.23M -0.37340M
Issuance of capital stock 0.00000M 4.23M 0.00000M 8.30M 0.00000M
Depreciation 2.49M 2.46M 2.35M 2.27M 1.52M
Other cashflows from investing activities - - 0.05M -0.00891M -0.01408M
Dividends paid - - - - -
Change to inventory -2.94856M -0.99746M 0.43M -0.18659M -0.28194M
Change to account receivables 0.94M -0.89743M -0.15964M -0.70487M 0.41M
Sale purchase of stock - - 0.00001M 8.30M 0.10M
Other cashflows from financing activities -28.65864M 0.41M 11.48M 0.00000M 1.29M
Change to netincome 287.39M 0.19M -0.64457M 0.36M 0.12M
Capital expenditures 3.98M 2.61M 4.07M 1.39M 2.03M
Change receivables - - -0.13238M -0.73262M 0.41M
Cash flows other operating - - -0.98336M -0.08768M 0.12M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - 0.66M 3.77M -1.27776M
Change in working capital -1.83269M -1.62251M 0.53M -1.09560M 0.30M
Stock based compensation 0.27M 0.14M 0.25M 0.31M 0.34M
Other non cash items 0.03M 0.02M -0.78035M 0.02M -0.68144M
Free cash flow -5.51914M -1.65448M -2.75696M -1.15793M -2.40330M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ICCC
ImmuCell Corporation		 0.09 0.94% 9.70 - - 2.23 1.56 3.13 -21.1926
NVO
Novo Nordisk A/S		 -1.94 4.52% 41.02 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -2.11 4.87% 41.25 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.87 0.87% 442.96 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -24.11 3.79% 611.34 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

ImmuCell Corporation

56 Evergreen Drive, Portland, ME, United States, 04103

Key Executives

Name Title Year Born
Mr. Michael F. Brigham Pres, CEO, Principal Financial Officer, Treasurer, Sec. & Director 1961
Ms. Bobbi Jo Brockmann VP of Sales & Marketing and Director 1977
Ms. Elizabeth L. Williams VP of Manufacturing Operations 1956
Elizabeth S. Toothaker Director of Fin. & Admin. NA
Mr. A. Gustavo Scaffa Sr. Director of Quality NA
John W. Zinckgraf Director of Product Devel. NA
Mr. Michael F. Brigham President, CEO, Principal Financial Officer, Treasurer, Secretary & Director 1961
Elizabeth S. Toothaker Director of Finance & Administration and Controller NA
Mr. A. Gustavo Scaffa Senior Director of Quality NA
John W. Zinckgraf Director of Product Development NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions